Dogwood Therapeutics, Inc. (DWTX) Form 10-Q — Nov 6, 2026
Dogwood Therapeutics filed its Q3 2026 10-Q with a substantial-doubt going-concern disclosure: cash of $4.9 million plus $5 million raised in the October Sealbond private placement funds operations only through March 2027. The company posted a Q3 net loss of $4.9 million and a nine-month net loss of $21.4 million, including a $9.2 million non-cash IPR&D impairment on the Halneuron CINP asset earlier in 2026; goodwill and the remaining IPR&D asset remain at risk of further impairment.
Key figures
- Total Debt
- 0
- Total Assets
- 75608219
- Cash Position
- 4948266
- Shares Outstanding
- 38227913
- Runway through
- March 2027
- Accumulated deficit
- 129475481
- Sealbond offering shares
- 4098360
- Licensing revenue q3 2026
- 100000
- Net loss nine months 2025
- 30476921
- Net loss nine months 2026
- 21399165
- Halneuron phase2b patients
- 239
- Net loss three months 2026
- 4882942
- Iprd impairment nine months 2026
- 9190897
- Sealbond offering gross proceeds
- 5000000
- Sealbond offering price per share
- 1.22
- Operating cash outflow nine months 2026
- 12834643
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.